Clinical Study of Apatinib as the Second-line Therapy in Malignant Melanoma

NCT03383237 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER_GOV

Sponsor class

Conditions

Malignant Melanoma

Interventions

DRUG: Apatinib

Sponsor

Henan Cancer Hospital

Collaborators

[object Object]